The evaluation of esophageal adenocarcinoma using dynamic contrast-enhanced magnetic resonance imaging

Journal of Gastrointestinal Surgery

Volumn 12, Issue 1, 2008, Pages 166-175

  Chang, Eugene Y ^a   Li, Xin ^b   Jerosch Herold, Michael ^b   Priest, Ryan A ^a   Enestvedt, C Kristian ^a   Xu, Jingang ^b   Springer Jr , Charles S ^b   Jobe, Blair A ^a,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Dynamic contrast enhanced magnetic resonance imaging; Esophageal adenocarcinoma; Neoadjuvant chemoradiation

Indexed keywords

CONTRAST MEDIUM; DIAGNOSTIC AGENT; GADOLINIUM; GADOTERIDOL; HETEROCYCLIC COMPOUND; ORGANOMETALLIC COMPOUND;

ADENOCARCINOMA; ARTICLE; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; ESOPHAGUS TUMOR; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; REPRODUCIBILITY;

ADENOCARCINOMA; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; ESOPHAGEAL NEOPLASMS; GADOLINIUM; HETEROCYCLIC COMPOUNDS; HUMANS; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MALE; ORGANOMETALLIC COMPOUNDS; PILOT PROJECTS; REPRODUCIBILITY OF RESULTS;

EID: 38149009615     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-007-0253-5     Document Type: Article

References (54)

1. Daly JM, Karnell LH, Menck HR. National Cancer Data Base report on esophageal carcinoma. Cancer 1996;78:1820-1828.
2. Ide H, Nakamura T, Hayashi K, Endo T, Kobayashi A, Eguchi R, Hanyu F. Esophageal squamous cell carcinoma: pathology and prognosis. World J Surg 1994;18:321-330.
3. Torres C, Turner JR, Wang HH, Richards W, Sugarbaker D, Shahsafaei A, Odze RD. Pathologic prognostic factors in Barrett's associated adenocarcinoma: a follow-up study of 96 patients. Cancer 1999;85:520-528.
4. Gopal DV, Powers J. Barrett's esophagus and esophageal adenocarcioma: a pratical approach to diagnosis and management. Ann Long Term Care 2002;10:27-31.
5. Spechler SJ. Screening and surveillance for complications related to gastroesophageal reflux disease. Am J Med 2001;111(Suppl 8A):130S-136S.
6. Spechler SJ. Clinical practice. Barrett's esophagus. N Engl J Med 2002;346:836-842.
7. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
8. Stahl M, Wilke H, Stuschke M, Walz MK, Fink U, Molls M, Siewert JR, Schroeder M, Makoski HB, Schmidt U, Seeber S, Vanhoefer U. Clinical response to induction chemotherapy predicts local control and long-term survival in multimodal treatment of patients with locally advanced esophageal cancer. J Cancer Res Clin Oncol 2005;131:67-72.
9. Zuccaro G Jr, Rice TW, Goldblum J, Medendorp SV, Becker M, Pimentel R, Gitlin L, Adelstein DJ. Endoscopic ultrasound cannot determine suitability for esophagectomy after aggressive chemoradiotherapy for esophageal cancer. Am J Gastroenterol 1999;94:906-912.
10. Melcher L, Wong W, Sanghera B, Bentzen SM, Hall M, Chambers J. Sequential FDG-PET scanning in the assessment of response to neoadjuvant chemotherapy in operable oesophageal cancer. J Clin Oncol 2004;22:327s.
11. Jones DR, Parker LA Jr, Detterbeck FC, Egan TM. Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. Cancer 1999;85:1026-1032.
12. Hordijk ML, Kok TC, Wilson JH, Mulder AH. Assessment of response of esophageal carcinoma to induction chemotherapy. Endoscopy 1993;25:592-596.
13. Laterza E, de Manzoni G, Guglielmi A, Rodella L, Tedesco P, Cordiano C. Endoscopic ultrasonography in the staging of esophageal carcinoma after preoperative radiotherapy and chemotherapy. Ann Thorac Surg 1999;67:1466-1469.
14. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 1997;7:91-101.
15. Tofts PS, Berkowitz B, Schnall MD. Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model. Magn Reson Med 1995;33:564-568.
16. Couvelard A, Paraf F, Gratio V, Scoazec JY, Henin D, Degott C, Flejou JF. Angiogenesis in the neoplastic sequence of Barrett's oesophagus. Correlation with VEGF expression. J Pathol 2000;192:14-18.
17. Lord RV, Park JM, Wickramasinghe K, DeMeester SR, Oberg S, Salonga D, Singer J, Peters JH, Danenberg KD, Demeester TR, Danenberg PV. Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus. J Thorac Cardiovasc Surg 2003;125:246-253.
18. Torres C, Wang H, Turner J, Shahsafaei A, Odze RD. Prognostic significance and effect of chemoradiotherapy on microvessel density (angiogenesis) in esophageal Barrett's esophagus-associated adenocarcinoma and squamous cell carcinoma. Human Pathol 1999;30:753-758.
19. Auvinen MI, Sihvo EI, Ruohtula T, Salminen JT, Koivistoinen A, Siivola P, Ronnholm R, Ramo JO, Bergman M, Salo JA. Incipient angiogenesis in Barrett's epithelium and lymphangiogenesis in Barrett's adenocarcinoma. J Clin Oncol 2002;20:2971-2979.
20. Yankeelov TE, Rooney WD, Huang W, Dyke JP, Li X, Tudorica A, Lee J-H, Koutcher JA, Springer CS. Evidence for shutter-speed variation in CR bolus-tracking studies of human pathology. NMR Biomed 2005;18:173-185.
21. Huang W, Li X, Morris EA, Tudorica LA, Venkatraman ES, Wang Y, Xu J, Springer CS. Shutter speed analysis of CR bolus-tracking data facilitates discrimination of benign and malignant breast disease. Proc Int Soc Magn Reson Med 2007;15:141.
22. Li X, Huang W, Yankeelov TE, Tudorica A, Rooney WD, Springer CS. Shutter-speed analysis of contrast reagent bolus-tracking data: Preliminary observations in benign and malignant breast disease. Magn Reson Med 2005;53:724-729.
23. Li X, Rooney WD, Springer CS. A unified MRI pharmacokinetic theory: intravascular and extracellular contrast reagents. Magn Reson Med 2005;54:1351-1359 (Erratum: Magn Reson Med 2006;55:1217).
24. Yankeelov TE, Rooney WD, Li X, Springer CS. Variation of the relaxographic "shutter-speed" for transcytolemmal water exchange affects the CR bolus-tracking curve shape. Magn Reson Med 2003;50:1151-1169.
25. Zhou R, Pickup S, Yankeelov TE, Springer CS, Glickson JD. Simultaneous measurement of arterial input function and tumor pharmacokinetics in mice by dynamic contrast enhanced imaging: effects of transcytolemmal water exchange. Magn Reson Med 2004;52:248-257.
26. Knopp MV, Weiss E, Sinn HP, Mattern J, Junkermann H, Radeleff J, Magener A, Brix G, Delorme S, Zuna I, van Kaick G. Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 1999;10:260-266.
27. Knopp MV, von Tengg-Kobligk H, Choyke PL. Functional magnetic resonance imaging in oncology for diagnosis and therapy monitoring. Mol Cancer Ther 2003;2:419-426.
28. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223-232.
29. Hiraishi K, Narabayashi I, Fujita O, Yamamoto K, Sagami A, Hisada Y, Saika Y, Adachi I, Hasegawa H. Blueberry juice: preliminary evaluation as an oral contrast agent in gastrointestinal MR imaging. Radiology 1995;194:119-123.
30. Karantanas AH, Papanikolaou N, Kalef-Ezra J, Challa A, Gourtsoyiannis N. Blueberry juice used per os in upper abdominal MR imaging: composition and initial clinical data. Eur Radiol 2000;10:909-913.
31. Schmid MR, Hany TF, Knesplova L, Schlumpf R, Debatin JF. 3D MR gastrography: exoscopic and endoscopic analysis of the stomach. Eur Radiol 1999;9:73-77.
32. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462-467.
33. Mooney MM. Neoadjuvant and adjuvant chemotherapy for esophageal adenocarcinoma. J Surg Oncol 2005;92:230-238.
34. Donington JS, Miller DL, Allen MS, Deschamps C, Nichols FC 3rd, Pairolero PC. Tumor response to induction chemoradiation: influence on survival after esophagectomy. Eur J Cardiothorac Surg 2003;24:631-636; discussion 636-637.
35. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-2098.
36. Swisher SG, Ajani JA, Komaki R, Nesbitt JC, Correa AM, Cox JD, Lahoti S, Martin F, Putnam JB, Smythe WR, Vaporciyan AA, Walsh GL, Roth JA. Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 2003;57:120-127.
37. Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, Wang H, Goldberg M. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005;23:4330-4337.
38. Roth JA, Pass HI, Flanagan MM, Graeber GM, Rosenberg JC, Steinberg S. Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus. J Thorac Cardiovasc Surg 1988;96:242-248.
39. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, Minsky BD, Roth JA. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998;339:1979-1984.
40. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001;19:305-313.
41. Swisher SG, Hofstetter W, Wu TT, Correa AM, Ajani JA, Komaki RR, Chirieac L, Hunt KK, Liao Z, Phan A, Rice DC, Vaporciyan AA, Walsh GL, Roth JA. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg 2005;241:810-817; discussion 817-820.
42. Kim SB, Kim SH, Lee KH, Lee JW, Kim SW, Suh CW, Lee JS, Song HY, Chang HS, Choi EK, et al. Preoperative chemoradiotherapy for locoregional esophageal cancer: preliminary report. J Korean Med Sci 1995;10:111-120.
43. Yang Q, Cleary KR, Yao JC, Swisher SG, Roth JA, Lynch PM, Komaki R, Ajani JA, Rashid A, Hamilton SR, Wu TT. Significance of post-chemoradiation biopsy in predicting residual esophageal carcinoma in the surgical specimen. Dis Esophagus 2004;17:38-43.
44. Beseth BD, Bedford R, Isacoff WH, Holmes EC, Cameron RB. Endoscopic ultrasound does not accurately assess pathologic stage of esophageal cancer after neoadjuvant chemoradiotherapy. Am Surg 2000;66:827-831.
45. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA, Eloubeidi MA. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg 2005;129:1232-1241.
46. Flamen P, Van Cutsem E, Lerut A, Cambier JP, Haustermans K, Bormans G, De Leyn P, Van Raemdonck D, De Wever W, Ectors N, Maes A, Mortelmans L. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 2002;13:361-368.
47. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, Meisetschlager G, Busch R, Siewert JR, Schwaiger M, Fink U. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001;19:3058-3065.
48. Song SY, Kim JH, Ryu JS, Lee GH, Kim SB, Park SI, Song HY, Cho KJ, Ahn SD, Lee SW, Shin SS, Choi EK. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. Int J Radiat Oncol Biol Phys 2005;63:1053-1059.
49. Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Masuda N, Fukuchi M, Manda R, Tsukada K, Oriuchi N, Endo K. Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg 2002;184:279-283.
50. Brink I, Hentschel M, Bley TA, Walch A, Mix M, Kleimaier M, Moser E, Imdahl A. Effects of neoadjuvant radio-chemotherapy on 18F-FDG-PET in esophageal carcinoma. Eur J Surg Oncol 2004;30:544-550.
51. Downey RJ, Akhurst T, Ilson D, Ginsberg R, Bains MS, Gonen M, Koong H, Gollub M, Minsky BD, Zakowski M, Turnbull A, Larson SM, Rusch V. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 2003;21:428-432.
52. Brucher BL, Weber W, Bauer M, Fink U, Avril N, Stein HJ, Werner M, Zimmerman F, Siewert JR, Schwaiger M. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 2001;233:300-309.
53. Arslan N, Miller TR, Dehdashti F, Battafarano RJ, Siegel BA. Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]fluoro-D- glucose with positron emission tomography in patients with esophageal cancer. Mol Imaging Biol 2002;4:301-310.
54. Briel JW, Tamhankar AP, Hagen JA, DeMeester SR, Johansson J, Choustoulakis E, Peters JH, Bremner CG, DeMeester TR. Prevalence and risk factors for ischemia, leak, and stricture of esophageal anastomosis: gastric pull-up versus colon interposition. J Am Coll Surg 2004;198:536-541; discussion 541-532.